The Japanese company FujiFilm Diosynth Biotechnologies announced Thursday that it’s adding 680 jobs to a pharmaceutical manufacturing facility in Holly Springs.
The Global Pharmaceutical Drug Delivery Industry is on track for significant growth, driven by innovation and increasing demand for effective medications, according to a recent market analysis by Future Market Insights (FMI).
Chief executive Bill Anderson says he doesn’t want it to be a ‘lame’ company, but its stock has still tanked 50%.
Analysts have recently evaluated Collegium Pharmaceutical and provided 12-month price targets. The average target is $39.75, accompanied by a high estimate of $40.00 and a low estimate of $39.00. This upward trend is evident, with the current average reflecting a 7.43% increase from the previous average price target of $37.00.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,
The collective purchasing power wielded by LMICs marks a critical step towards achieving universal health access.
U.S. Attorney Philip Sellinger announced the deal settles allegations Novel Laboratories violated the Controlled Substances Act.
Chief executive Bill Anderson says he doesn’t want it to be a ‘lame’ company, but its stock has still tanked 50%.
Chief executive Bill Anderson says he doesn’t want it to be a “lame” company, but its stock has still tanked 50%.
In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report),